URL has been copied successfully!
WASHINGTON — Health industry leaders, still contending with the new rules of President Trump’s Washington, are about to face another shift.
November’s midterm elections are likely to shake up key health policy debates, from Medicaid funding to the price of medication. That’s especially true if Democrats seize control of a chamber of Congress, though any major policymaking would still need Trump’s signature.
Drawing on interviews with nearly a dozen leaders and lobbyists representing the health industry, these are the most important questions about federal policy after the midterms. How they are answered will have wide-ranging impacts for America’s health system, science, and patients.
Please follow us:
